BCR and lymphoma: This hallmark of B cell–derived lymphoma is considered an oncogenic and prosurvival signal and underlies the rationale for using BCR inhibitors to target downstream kinases such as BTK, SYK, and PI3Kδ (Burger and Wiestner, 2018).